Evaxion A (EVAX) Revenue (2024 - 2025)
Evaxion A (EVAX) reported Revenue of $7.5 million for Q3 2025, up 148.33% on a YoY basis from $3.0 million in Q3 2024, and down 99.98% quarter-over-quarter from $37.0 billion in Q2 2025.
Evaxion A (EVAX) Revenue (2024 - 2025) Analysis & Trends
Evaxion A has reported Revenue for 2 years, with the latest figure at $7.5 million in Q3 2025.
- For the quarter ending Q3 2025, Revenue rose 148.33% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.0 billion (up 1123723.02% YoY), and the FY2025 full-year result was $7.5 million, up 125.12% from the prior year.
- Revenue for Q3 2025 stood at $7.5 million, down from $37.0 billion in the prior quarter.
- The five-year high for Revenue was $37.0 billion in Q2 2025, with the low at $51000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 3.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | 37.00 Bn |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 51,000.00 |